source
- ResMed issues correction for Astral ventilators due to electrical component failure riskResMed has released a correction for certain Astral ventilators after identifying a faulty electrical component that could interrupt therapy and cause serious injury or death. The FDA classifies t…
- Novo Nordisk's ziltivekimab fails phase 3 trial, jeopardizing CKD programNovo Nordisk reported that its phase 3 Zeus trial of the IL‑6 ligand antibody ziltivekimab did not meet its primary endpoint, a setback for the drug's development. The study enrolled more than 6,3…